Specialized Research

Mazdutide

Molecular Identifiers

Molecular Formula

C207H317N45O65

PubChem CID

167312357

Overview

Dual GLP-1/Glucagon agonist. Metabolic research. Gradual dose escalation recommended. Weekly administration.

Approved by NMPA (China) in June 2025 for the treatment of obesity in adults, developed by Innovent Biologics. Dual GLP-1/Glucagon agonist with results of up to 18% weight loss in clinical trials. Global phase 3 trials ongoing.

Sequence (1 letter): HSQGTFTSDYSKYLDERAAQDFVQWLLDGGPSSGQPPPS

Extended notation:

His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Arg-Ala-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Leu-Asp-Gly-Gly-Pro-Ser-Ser-Gly-Gln-Pro-Pro-Pro-Ser (with C20 fatty acid-PEG linker at Lys12)

Modified peptide — dual GLP-1/Glucagon agonist with chemical modifications for extended half-life

Half-life

~5-7 days

Administration Route

Subcutaneous

Mechanism of Action

GLP-1 receptor agonism (satiety, insulin secretion)
Glucagon receptor agonism (hepatic lipolysis, thermogenesis)
Dual effect for weight loss and glycemic control

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter	Value
Dose	3-6 mg per week (typically)
Frequency	Once per week
Timing	Same day/time each week
Duration	12-24 weeks

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

Nausea
Vomiting
Diarrhea
Abdominal pain
Decreased appetite

Product Properties

Purity	>95%
Appearance	White lyophilized powder
Solubility	Soluble in water and bacteriostatic water
Source	Recombinant DNA technology with post-translational chemical modification (fatty acid-PEG conjugation)
Storage	Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles.